Cipher Pharmaceuticals Inc.
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Craig Mull
- Full Time Employees
- 43
- Sector
- Health technology
- Industry
- Pharmaceuticals: other
- Address
- 5750 Explorer Drive Mississauga ON Canada L4W 0A9
- IPO Date
- Feb 25, 2004
- Website
- cipherpharma.com
- Similar Companies
- Business
- Cipher Pharmaceuticals Inc. is a specialty pharmaceutical company focused on the acquisition, development, and commercialization of prescription products in therapeutic areas including dermatology, women’s health, urology, and acute care. Its core product portfolio includes commercial products such as Natroba and its authorized generic Spinosad for the topical treatment of head lice and scabies; Epuris, an oral isotretinoin treatment for severe acne; Absorica, an oral retinoid for severe nodular and inflammatory acne; Actikerall for the treatment of actinic keratosis; Vaniqa, a topical cream that slows the growth of unwanted facial hair; Durela, an opioid analgesic for moderate to moderately severe pain management; Brinavess for rapid conversion of atrial fibrillation to sinus rhythm; and Aggrastat, an intravenous GP IIb/IIIa inhibitor for acute coronary syndrome. Its licensed products further include Lipofen for hyperlipidemia and Conzip, an opioid agonist for chronic pain management. In its pipeline, Cipher develops products such as MOB-015, a topical terbinafine formulation for onychomycosis in phase 3 clinical trials; CF-101 (Piclidenoson) for severe plaque psoriasis and rheumatoid arthritis in phase 3; and DTR-001, a tattoo removal cream in pre-clinical stages. The company operates primarily in Canada, with commercial reach into the U.S. and South America. Founded in 2000, it is headquartered in Oakville, Canada. Recent major developments include Cipher Pharmaceuticals’ 2024 acquisition of the Natroba product line and ParaPRO LLC’s dermatology commercial infrastructure, significantly expanding its dermatology platform and doubling its current sales and earnings base. The acquisition reinforces Cipher’s strategy to establish a leading dermatology franchise featuring innovative and unique products. Cipher has also secured Medicaid step-through preferred status for Natroba in Illinois and continues to invest in growing market share for Natroba in the U.S., including planned commercialization in Canada following Health Canada regulatory approval. The company is actively pursuing additional business development opportunities including acquisitions, in-licensing, and out-licensing globally to enhance its North American platform and expand its product portfolio. It recently closed a $35 million credit facility to support growth initiatives and continues to leverage its strong sales force and Canadian dermatology market presence for new product launches and expansions. Cipher Pharmaceuticals manages a broad portfolio of commercial and early to late-stage specialty pharmaceutical products addressing unmet medical needs, with direct marketing efforts in Canada and partnerships in the U.S. and other regions. The company's focus on dermatology and specialty medicines is supported by strategic acquisitions, selective investments in drug development, and a diversified approach to commercializing prescription products with sustained growth prospects in North American and global markets.
Company News
Cipher Pharmaceuticals (TSE:CPH) Stock Price Crosses Below Fifty Day Moving Average – Time to Sell?
Cipher Pharmaceuticals (TSE:CPH) Stock Crosses Below Fifty Day Moving Average – Here’s Why
Cipher Pharmaceuticals (TSE:CPH) Director Craig Mull Acquires 20,000 Shares of Stock
Cipher Pharmaceuticals (TSE:CPH) Shares Pass Below 50-Day Moving Average – Time to Sell?
Cipher Pharmaceuticals (OTCMKTS:CPHRF) Share Price Crosses Below 200-Day Moving Average – Should You Sell?
Cipher Pharmaceuticals Inc. (CPH:CA) Q1 2026 Earnings Call Transcript
CaryHealth Launches Direct-to-Patient Program for Cipher Pharmaceuticals' Natroba™ (spinosad)
Cipher Pharmaceuticals (OTCMKTS:CPHRF) Stock Price Crosses Above 50 Day Moving Average – Should You Sell?
Cipher Pharmaceuticals Inc. (CPH:CA) Q4 2025 Earnings Call Transcript
Cipher Pharmaceuticals (OTCMKTS:CPHRF) Stock Price Passes Above Fifty Day Moving Average – Should You Sell?
Cipher Pharmaceuticals Inc. (CPH:CA) Q3 2025 Earnings Call Transcript
Halvio Capital Q3 2025 Position Updates
Cipher Pharmaceuticals Inc. (CPHRF) Q2 2025 Earnings Call Transcript
Cipher Pharmaceuticals Inc. (CPHRF) Q1 2025 Earnings Call Transcript
Most Topical Earnings Summaries And Commentary For April 2025
Cipher Pharmaceuticals Inc. (CPHRF) Q4 2024 Earnings Call Transcript
Cipher Pharmaceuticals Inc. (CPHRF) Q1 2024 Earnings Call Transcript
Cipher Pharmaceuticals Announces Participation in the 2024 Bloom Burton & Co. Healthcare Investor Conference
Cipher Pharmaceuticals Inc. (CPHRF) Q3 2023 Earnings Call Transcript
Cipher Pharmaceuticals Inc. (CPHRF) Q2 2023 Earnings Call Transcript